On May 13, MSD announced the termination of the ongoing MK-7684A（Pembrolizumab+VIbostolimab versus Pembrolizumab MonotherapyAdjuvant Treatment Post-Surgical ResectionStage IIB-IVPhase III KeyVibe-010 Study in High-Risk Melanoma Patients.The reason for termination is that the studyIn pre-plannedIn the analysisMet the criterion for futility, i.e.,MK-Group 7684A PatientsRelapse-Free Survival Period(RFS) compared to the pembrolizumab monotherapy group did not significantly extend。AndPembrolizumabAnti-monotherapy GroupIn comparison,MK-Group 7684AA higher proportion of patients discontinued all adjuvant therapies, primarily due to immune-mediated adverse reactions, thusMK-Group 7684AExtremely unlikely to significantly outperform in terms of RFSPembrolizumabAnti-monotherapy Group。Based on the recommendation of the independent Data Monitoring Committee (DMC), MSD is unblinding this study and recommending acceptance.MK-7684APatients receiving treatment can choose to receive pembrolizumab monotherapy. The data analysis of this study is currently underway, and MSD will announce detailed data in the near future.Vibostolimab is an anti-TIGIT monoclonal antibody developed by MSD. It can restore anti-tumor activity by blocking the binding of the TIGIT receptor to its ligands (CD112 and CD155), thereby activating T lymphocytes that help destroy tumor cells.BesidesIn addition to the KeyVibe-010 study, MSD has also conducted four Phase III studies to evaluateMK-The Anti-Cancer Potential of 7684A:MSD stated that although the results of the KeyVibe-010 study were unsatisfactory, the remaining studies would not be affected and would continue as planned.Melanoma is the most serious form of skin cancer, characterized by the uncontrolled growth of pigment-producing cells. In the past few decades, the incidence of melanoma has been on the rise, with more than 330,000 new cases diagnosed globally in 2022. It is estimated that in 2024, in the United StatesNew Diagnosis of MelanomaCaseWill exceed 100,000 cases.Copyright © 2024 PHARMCUBE. All Rights Reserved.
Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position.For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.
Disclaimer: The information in this WeChat article is for general reference only and should not be used directly as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.↑Long press to scan the QR code, fill in the form to register↑
